RDUS - ラディウス・ヘルス (Radius Health Inc.) ラディウス・ヘルス

 RDUSのチャート


 RDUSの企業情報

symbol RDUS
会社名 Radius Health Inc (ラディウス・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ラジウス・ヘルス(Radius Health Inc)は生物医薬品企業である。同社は骨粗鬆症、腫瘍学および内分泌疾患の分野における治療法の開発に焦点を当てる。同社の治験薬候補であるTYMLOS(アバロパラチド-SC)注射は骨折リスクの高い骨粗鬆症を有する閉経後女性の治療のために開発される。同社の臨床パイプラインには骨粗鬆症に使用する可能性のある治験用アバロパラチド経皮パッチと、ホルモン駆動またはホルモン耐性乳がん、閉経後女性の血管運動症状の潜在的使用に関する治験薬elacestrant(RAD1901)を含まれる。RAD140は非ステロイド系の選択的アンドロゲン受容体モジュレーター(SARM)である。RAD140はホルモン受容体陽性乳癌の潜在的使用のために開発される。   ラディウス・ヘルスは、米国の婦人科領域に特化したバイオ医薬品会社。骨粗鬆症患者向け治療薬を開発するだけでなく、他の内分泌媒介性疾患に焦点を当て事業を展開。主要製品候補は、骨粗鬆症の治療のための骨同化皮下注射Abaloparatide-SC。臨床製品ポ―トフォリオとしては、経口薬で選択的エストロゲン受容体低下剤RAD1901がある。   Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.
本社所在地 950 Winter Street Waltham MA 02451 USA
代表者氏名 Kurt C. Graves Kurt C. Graves
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-551-4000
設立年月日 39479
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 561人
url www.radiuspharm.com
nasdaq_url https://www.nasdaq.com/symbol/rdus
adr_tso
EBITDA EBITDA(百万ドル) -242.34700
終値(lastsale) 18.83
時価総額(marketcap) 856321647.65
時価総額 時価総額(百万ドル) 862.23360
売上高 売上高(百万ドル) 58.30800
企業価値(EV) 企業価値(EV)(百万ドル) 803.73660
当期純利益 当期純利益(百万ドル) -259.29700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Radius Health Inc revenues increased from $980K to $37.2M. Net loss increased 4% to $130.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 26% to $49.2M (expense) General and administrative increase of 10% to $96.6M (expense).

 RDUSのテクニカル分析


 RDUSのニュース

   Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.  2021/06/23 16:00:00 Clinical Trials Gov
Condition : Osteoporosis Interventions : Combination Product: abaloparatide-sMTS (Patheon); Combination Product: abaloparatide-sMTS (Kindeva) Sponsors : Radius Health, Inc.; Medpace, Inc. Completed
   Sarcopenia Treatment Market Reviewed in Latest Study | GlaxoSmithKline, Radius Health, Five Prime Therapeutics  2021/06/08 07:43:29 OpenPR
Coherent Market Insights has added a new report to its database that qualifies an expressive and professional look into this market. The report is titled Global Sarcopenia Treatment Market. Thus, the report scrutinizes the present-day environment of the market in
   Radius Health (RDUS) falls 2.07% for May 19  2021/05/19 22:00:24 Equities
Radius Health (NASDAQ: RDUS) shares fell -2.07% to end trading Wednesday at $19.88 per share - a net change of $-0.42. Shares traded between $20.31 and $19.44 throughout the day. 219549 shares of Radius Health exchanged hands. Visit Radius Healths profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Radius Health and to follow the companys latest updates, you can visit the companys profile page here: Radius Healths Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by Barchart as of 4:30pm ET on the day of publication.
   Radius Health (NASDAQ:RDUS) PT Raised to $24.00 at SVB Leerink  2021/05/12 07:54:41 Transcript Daily
Radius Health (NASDAQ:RDUS) had its price objective boosted by research analysts at SVB Leerink from $23.00 to $24.00 in a report released on Monday, Price Targets.com reports. The brokerage presently has a market perform rating on the biopharmaceutical companys stock. SVB Leerinks target price points to a potential upside of 16.96% from the stocks current []
   Radius Health Inc Shares Close the Week 37.3% Higher - Weekly Wrap  2020/12/18 22:30:00 Kwhen Finance
Radius Health Inc shares closed the week 37.3% higher than it did at the end of last week. The stock is currently down 3.5% year-to-date, down 9.3% over the past 12 months, and down 67.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 1.2%. Trading Activity Shares traded as high as $19.60 and as low as $14.20 this week. Shares closed 1e+1% below its 52-week high and 9e+1% above its 52-week low. Trading volume this week was 8.3% lower than the 10-day average and 51.7% higher than the 30-day average. Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. MACD, a trend-following momentum indicator, indicates an upward trend. The stock closed below its Bollinger band, indicating it may be oversold. The stock closed at 11.6% higher than its 5-day moving average, 24.1% higher than its 20-day moving average, and 44.2% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio lags its average peer by -121.7% The company's performance over the last 1 year lags its average peer by -134.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
   Leerink Partners Stick to Their Hold Rating for Radius Health By Investing.com  2021/01/07 12:33:48 Investing.com
Leerink Partners Stick to Their Hold Rating for Radius Health
   Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada  2021/01/05 13:36:00 PR Newswire
DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis…
   Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada  2021/01/05 13:15:00 GlobeNewswire
Agreement incorporates TYMLOS® and abaloparatide-TDConsideration includes upfront payment, milestones based on clinical, regulatory and commercial…
   Radius Health Announces Change to its Board of Directors  2021/01/04 21:30:00 GlobeNewswire
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr….
   Leerink Partners Stick to Their Hold Rating for Radius Health By Investing.com  2021/01/07 12:33:48 Investing.com
Leerink Partners Stick to Their Hold Rating for Radius Health
   Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada  2021/01/05 13:36:00 PR Newswire
DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis…
   Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada  2021/01/05 13:15:00 GlobeNewswire
Agreement incorporates TYMLOS® and abaloparatide-TDConsideration includes upfront payment, milestones based on clinical, regulatory and commercial…
   Radius Health Announces Change to its Board of Directors  2021/01/04 21:30:00 GlobeNewswire
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr….
   Radius Health, Inc. (NASDAQ:RDUS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?  2020/11/09 12:39:22 Yahoo Finance
Radius Health, Inc. (NASDAQ:RDUS) last week reported its latest third-quarter results, which makes it a good time for…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ラディウス・ヘルス RDUS Radius Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)